SCHEMBL4155293

SCHEMBL4155293

O=C(O)CNC(=O)c1c(O)c2sccc2[nH]c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 5/20 0.57
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
RXFP1 Q9HBX9 1/20 0.46
KDM4E B2RXH2 4/20 0.44
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
PKM P14618 1/20 0.43
KDM5A P29375 1/20 0.41
USP2 O75604 1/20 0.39
HPGD P15428 1/20 0.39
LMNA P02545 2/20 0.37
MAPT P10636 2/20 0.37
PARP1 P09874 1/20 0.36
CSNK2A2 P19784 1/20 0.36
CSNK2B P67870 1/20 0.36
CSNK2A1 P68400 1/20 0.36
KCNH2 Q12809 1/20 0.36
ALDH1A1 P00352 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4154430 0.80 EGLN1 (0.47) EGLN1MEN1KMT2ARXFP1KDM4E
SCHEMBL7308279 0.79 PARP1 (0.47) KDM4EHPGDPARP1CSNK2A2CSNK2B
SCHEMBL8852483 0.78 KDM4E (0.42) MEN1KMT2AKDM4ERAB9AKDM5A
SCHEMBL22640127 0.77 HSD17B10 (0.52) MEN1KMT2ARXFP1KDM4EPKM
SCHEMBL821620 0.77 KMT2A (0.76) MEN1KMT2ARXFP1KDM4ERAB9A
SCHEMBL5311454 0.75 MEN1 (0.54) MEN1KMT2ARXFP1KDM4ERAB9A
SCHEMBL8807295 0.74 SLC22A12 (0.56) MEN1KMT2AKDM4ERAB9ANPC1
SCHEMBL5304938 0.74 KDM4E (0.51) MEN1KMT2ARXFP1KDM4ERAB9A
SCHEMBL5308306 0.73 KDM4E (0.53) EGLN1MEN1KMT2ARXFP1KDM4E
SCHEMBL2086443 0.73 KDM5A (0.76) MEN1KMT2ARXFP1KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090176825-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-07-09 US claimed
US-20090176825-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-07-09 US disclosed
US-20090176825-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-07-09 US disclosed
US-20090176825-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-07-09 US disclosed
WO-2007136990-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176825-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 EGLN1 6/4885MEN1 3087/4885KMT2A 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.